Interestingly, atezolizumab, another anti–PD-L1 monoclonal antibody, showed durable clinical benefit in some women with advanced or recurrent endometrial cancer, and the clinical benefit appeared to increase with higher PD-L1 expression [10]. Here, CD274 is linked to endometrial cancer.